This post was originally published on this site
https://d1-invdn-com.investing.com/content/pic7e9262df32be76051742b8882053ab5e.jpg
Barring a few transactions in names like chipmaker Nvidia (NASDAQ:NVDA) and Tesla (NASDAQ:TSLA), Wood’s Ark Investment Management LLC has largely been picking up smaller stocks including automation software provider Uipath Inc (NYSE:PATH), biotech firm Ginkgo Bioworks Holdings (NYSE:DNA) and space systems company Rocket Lab USA, Inc. (NASDAQ:RKLB) since Sept. 13, according to data compiled by Bloomberg.
That’s a change from when Ark funds bought Tesla in 10 sessions from the last week of May to mid-June after the electric carmaker lost its crown jewel status in her main fund, a position it had held for about four-and-a-half years.
Wood’s leaning toward smaller stocks came after markets tumbled in the wake of hotter-than-expected US inflation and another jumbo rate hike by the Federal Reserve in September.
Ark ranks as the second biggest shareholder in UiPath and the fifth largest in Ginkgo, while Rocket Lab is a relatively recent addition to its funds.
Some of the smaller stocks have fallen a lot more than larger companies this year, which would have burnished their appeal amid any bargain hunting. For example, UiPath, Ginkgo and Rocket Lab are each down more than 60% year-to-date, compared to a 21% decline for both the Russell 2000 Index and the S&P 500 benchmark.
READ: Ginkgo Bioworks Hits Six-Week High as Ark Funds Buy Shares
To be sure, Wood still bought Tesla shares on Monday following a decline in the aftermath of the company’s disappointing delivery numbers.
Ark’s flagship ARK Innovation ETF (NYSE:ARKK) has plunged 58% in 2022 as historical tightening by the Federal Reserve and global recession fears batter growth stocks.
©2022 Bloomberg L.P.
